Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Loxiglumide (CR-1505) 是一种缩胆囊素受体拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 283 | 现货 | ||
10 mg | ¥ 498 | 现货 | ||
25 mg | ¥ 996 | 现货 | ||
50 mg | ¥ 1,820 | 现货 | ||
100 mg | ¥ 3,550 | 现货 | ||
500 mg | ¥ 7,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 283 | 现货 |
产品描述 | Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor. |
激酶实验 | Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH?8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104. |
别名 | CR-1505, 氯谷胺 |
分子量 | 461.38 |
分子式 | C21H30Cl2N2O5 |
CAS No. | 107097-80-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.61 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1674 mL | 10.8371 mL | 21.6741 mL | 54.1853 mL |
5 mM | 0.4335 mL | 2.1674 mL | 4.3348 mL | 10.8371 mL | |
10 mM | 0.2167 mL | 1.0837 mL | 2.1674 mL | 5.4185 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Loxiglumide 107097-80-3 GPCR/G Protein cholecystokinin CR-1505 氯谷胺 CCK Receptor Inhibitor CR1505 CR 1505 inhibit Cholecystokinin Receptor inhibitor